NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease Newamsterdampharma. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion Newamsterdampharma. They acquired the rights to obicetrapib, a once-abandoned CETP inhibitor, from an Amgen subsidiary in 2020 Newamsterdampharma. Soon after, Dr. Michael Davidson joined as co-founder and CEO, bringing deep clinical expertise to the leadership team Newamsterdampharma.
